iCad shakes up its board of directors

iCad (NSDQ:ICAD) shook up its board of directors after a member tendered his resignation, naming a new chairman and re-jiggering the composition of its oversight committees. Andy Sassine, a longtime shareholder who owns a 7.5% stake in the cancer detection company, joined the board in 2015. In his Sept. 26 resignation letter, Sassine said he grew disenchanted with the board’s seeming unwillingness to properly guide iCad. “I can no longer stand idly by while the Board’s inaction and misdirection directly harms the interests of iCad’s shareholders,” Sassine wrote, citing the board’s failure to examine the firm’s poor stock performance, “questionable” governance practices including “a long-tenured board in dire need of a refresh” and executive compensation packages that have grown even as management missed its operational and revenue targets three years in a row. “It has become clear to me that the board, as currently constituted, is truly incapable of acting independently of management and taking the steps required to enhance shareholder value. That I have not been appointed to a single board committee over the past three years speaks to this board’s general unwillingness to consider independent views in the boardroom,” Sassine wrote. “Debate in the board room is critical to allow for the productive analysis of the important issues facing the company. But rather than engage in an open, rob...
Source: Mass Device - Category: Medical Devices Authors: Tags: Oncology Wall Street Beat iCad Inc. Source Type: news

Related Links:

Men with clinically detected prostate cancer who had a long life expectancy lived for an additional 2.9 years following radical prostatectomy compared with patients who underwent watchful waiting.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
CONCLUSION: The immunodot kit allowed the diagnosis of 10 dermatomyositis. A high number of autoantibody positive patients without dermatomyositis raises the issue of the immunodot's performances in the context of biological autoimmunity. PMID: 30527961 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Authors: Longvert C, Saiag P Abstract Incidence of malignant melanoma has been increasing since the 1980s. For loco-regional stages, surgery is still the best treatment. Melanoma has a high distant metastatic potential and prognosis of advanced stages was until recently very poor. Since 2011 however, a real revolution has taken place in the treatment of metastatic melanoma. This is based upon considerably improved knowledge of the molecular mechanisms of melanoma and cancer immunology. Thus, two new classes of systemic therapeutic agents are now available: immunotherapies (immunological checkpoint inhibitors), whic...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Conclusion: We did not observe a positive association between the use of 5ARIs and MBC. The small number of breast cancer cases exposed to 5ARIs and the lack of an association in our study suggest that the development of breast cancer should not influence the prescribing of 5ARIs therapy.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
ABSTRACT Purpose: To provide data of the incidence and management of common urological malignancies in renal transplant recipients. Materials and Methods: We conducted a retrospective analysis of a prospective database from August 1967 to August 2015. A descriptive analysis of the sample was performed. Results: Among 1256 consecutive RTR a total of 88 patients developed malignancies (7%). There were 18 genitourinary tumors in the 16 patients (20.45 % of all malignant neoplasms), incidence of 1.27%. The most common neoplasm encounter was renal cancer (38.8%), followed by urothelial carcinoma (33.3%). Median follow-up of tra...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Conclusions: Diffusion restriction with lower ADC-values is the best parameter to predict cancer on MRI prior to biopsy. Efforts to establish an ADC cutoff value would improve cancer detection, especially for less experience reader.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
ABSTRACT Purpose: The purpose of our study was to evaluate the clinical impact of 68Ga-PSMA PET / CT in the setting of biochemical recurrence of prostate cancer. Materials and Methods: We retrospectively evaluated 125 prostate cancer patients submitted to the 68Ga-PSMA PET / CT due to biochemical recurrence. The parameters age, Gleason score, PSA levels, and the highest SUVmax were correlated to potential treatment changes. The highest SUVmax values were correlated with age and Gleason score. The median follow-up time was 24 months. Results: 68Ga-PSMA PET / CT led to a treatment change in 66 / 104 (63.4%) patients (twenty-...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
ABSTRACT Objectives: To test the ability of dynamic 11C-PET / CT to discriminate cancerous tissue from background tissue in patients with localized prostate cancer. Materials and Methods: Twenty-four consecutive patients with prostate cancer were prospectively evaluated with dynamic 11C-choline PET / CT prior to radical prostatectomy. The PET / CT scan was divided into 18 sequences of 5 seconds each, followed by 9 sequences of 60 seconds each. Whole-mount sections of harvested prostates served as reference standards. Volumes of interest were positioned on the dynamic PET / CT images and the following quantitative variables...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology